The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders—a double-blind, randomized, placebo-controlled proof-of-concept study

URN to cite this document:: urn:nbn:de:bvb:355-epub-583542
DOI to cite this document:: 10.5283/epub.58354

Brunner, Lisa-Marie

; Riebel, Marco ; Wein, Simon ; Koller, Michael

; Zeman, Florian ; Huppertz, Gunnar ; Emmer, Tanja ; Eberhardt, Yvonne ; Schwarzbach, Jens ; Rupprecht, Rainer ; Nothdurfter, Caroline

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 29 May 2024 11:01

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background Recent developments suggest that neurosteroids may achieve rapid antidepressant effects. As such, neurosteroidogenesis mediated by the translocator protein 18 kDa (TSPO) might constitute a promising option for the treatment of depression. Therefore, the current clinical trial aims to get the first evidence of whether TPSO ligands promote rapid antidepressant effects. Furthermore, we ...